Oncologic outcomes in patients undergoing maximal or optimal cytoreductive surgery for Stage 3C serous ovarian, tubal or peritoneal carcinomas

References

• Bakkar R, Gershenson D, Fox P, Vu K, Zenali M, Silva E. 2014. Stage IIIC ovarian/peritoneal serous carcinoma: a heterogeneous group of patients with different prognoses. International Journal of Gynecological Pathology 33:302–308.
   PubMed Web of Science ®Google Scholar
• Bao L, Ding Y, Cai Q, Ning Y, Hu W, Xue X. 2016. Primary fallopian tube carcinoma: a single-institution experience of 101 cases: a retrospective study. International Journal of Gynecological Cancer 26:424–430.
   PubMed Web of Science ®Google Scholar
• Benedet JL, Bender H, Jones H, 3rd, Ngan HY, Pecorelli S. 2000. FIGO staging classifications and clinical practice guidelines in the management of gynecologic cancers. FIGO Committee on Gynecologic Oncology. International Journal of Gynecology & Obstetrics 70:209–262.
   PubMed Web of Science ®Google Scholar
• Berek JS, Crum C, Friedlander M. 2015. Cancer of the ovary, fallopian tube, and peritoneum. International Journal of Gynecology & Obstetrics 131:S111–S122.
   PubMed Web of Science ®Google Scholar
• Berek JS. 2009. Lymph node-positive stage IIIC ovarian cancer: a separate entity? International Journal of Gynecological Cancer 19(Suppl. 2):S18–S20.
   PubMed Web of Science ®Google Scholar
• Callahan MJ, Crum CP, Medeiros F, Kindelberger DW, Elvin JA, Garber JE, et al. 2007. Primary fallopian tube malignancies in BRCA-positive women undergoing surgery for ovarian cancer risk reduction. Journal of Clinical Oncology 25:3985–3990.
   PubMed Web of Science ®Google Scholar
• Camara O, Sehouli J. 2009. Controversies in the management of ovarian cancer-pros and cons for lymph node dissection in ovarian cancer. Anticancer Research 29:2837–2843.
   PubMed Web of Science ®Google Scholar
• Carlson JW, Miron A, Jarboe EA, Parast MM, Hirsch MS, Lee Y, et al. 2008. Serous tubal intraepithelial carcinoma: its potential role in primary peritoneal serous carcinoma and serous cancer prevention. Journal of Clinical Oncology 26:4160–4165.
   PubMed Web of Science ®Google Scholar
• Chan JK, Urban R, Hu JM, Shin JY, Husain A, Teng NN, et al. 2007. The potential therapeutic role of lymph node resection in epithelial ovarian cancer: a study of 13918 patients. British Journal of Cancer 96:1817–1822.
   PubMed Web of Science ®Google Scholar
• Chang SJ, Bristow RE, Ryu HS. 2012. Impact of complete cytoreduction leaving no gross residual disease associated with radical cytoreductive surgical procedures on survival in advanced ovarian cancer. Annals of Surgical Oncology 19:4059–4067.
   PubMed Web of Science ®Google Scholar
• Chi DS, Eisenhauer EL, Lang J, Huh J, Haddad L, Abu-Rustum NR, et al. 2006. What is the optimal goal of primary cytoreductive surgery for bulky stage IIIC epithelial ovarian carcinoma (EOC)? Gynecologic Oncology 103:559–564.
   PubMed Web of Science ®Google Scholar
• Di Re F, Baiocchi G. 2000. Value of lymph node assessment in ovarian cancer: status of the art at the end of the second millennium. International Journal of Gynecological Cancer 10:435–442.
   PubMed Web of Science ®Google Scholar
• Du Bois A, Reuss A, Harter P, Pujade-Lauraine E, Ray-Coquard I, Pfisterer J. 2010. Potential role of lymphadenectomy in advanced ovarian cancer: a combined exploratory analysis of three prospectively randomized phase III multicenter trials. Journal of Clinical Oncology 28:1733–1739.
   PubMed Web of Science ®Google Scholar
• Einhorn N, Nilsson B, Sjovall K. 1985. Factors influencing survival in carcinoma of the ovary. Study from a well-defined Swedish population. Cancer 55:2019–2025.
   PubMed Web of Science ®Google Scholar
• Hacker NF, Berek JS, Lagasse LD, Nieberg RK, Elashoff RM. 1983. Primary cytoreductive surgery for epithelial ovarian cancer. Obstetrics and Gynecology 61:413–420.
   PubMed Web of Science ®Google Scholar
• Harter P, Sehouli J, Lorusso D, Reuss A, Vergote I, Marth C, et al. 2019. A randomized trial of lymphadenectomy in patients with advanced ovarian neoplasms. The New England Journal of Medicine 380:822–832.
   PubMed Web of Science ®Google Scholar
• Horng HC, Teng SW, Lai CR, Chang WH, Chang YH, Yen MS, et al. 2014. Prognostic factors of primary fallopian tube cancer in a single institute in Taiwan. International Journal of Gynecology & Obstetrics 127:77–81.
   PubMed Web of Science ®Google Scholar
• Kaban A, Topuz S, Saip P, Sözen H, Salihoğlu Y. 2018. Prognostic factors in patients undergoing primary cytoreductive surgery for FIGO stage IIIC ovarian, tubal or peritoneal cancer. Journal of Obstetrics and Gynaecology Canada 40:447–453.
   PubMed Web of Science ®Google Scholar
• Kindelberger DW, Lee Y, Miron A, Hirsch MS, Feltmate C, Medeiros F, et al. 2007. Intraepithelial carcinoma of the fimbria and pelvic serous carcinoma: evidence for a causal relationship. The American Journal of Surgical Pathology 31:161–169.
   PubMed Web of Science ®Google Scholar
• Kurman RJ, Carcangiu ML, Herrington CS. 2014. World Health Organisation classification of tumours of the female reproductive organs: international agency for research on cancer. Lyon: International Agency for Research on Cancer.
   Google Scholar
• Kurman RJ, Shih Ie M. 2008. Pathogenesis of ovarian cancer: lessons from morphology and molecular biology and their clinical implications. International Journal of Gynecological Pathology 27:151–160.
   PubMed Web of Science ®Google Scholar
• Levanon K, Crum C, Drapkin R. 2008. New insights into the pathogenesis of serous ovarian cancer and its clinical impact. Journal of Clinical Oncology 26:5284–5293.
   PubMed Web of Science ®Google Scholar
• Meinhold-Heerlein I, Fotopoulou C, Harter P, Kurzeder C, Mustea A, Wimberger P, et al. 2016. The new WHO classification of ovarian, fallopian tube, and primary peritoneal cancer and its clinical implications. Archives of Gynecology and Obstetrics 293:695–700.
   PubMed Web of Science ®Google Scholar
• Mery E, Jouve E, Guillermet S, Bourgognon M, Castells M, Golzio M, et al. 2011. Intraoperative fluorescence imaging of peritoneal dissemination of ovarian carcinomas. A preclinical study. Gynecologic Oncology 122:155–162.
   PubMed Web of Science ®Google Scholar
• Nezhat FR, Apostol R, Nezhat C, Pejovic T. 2015. New insights in the pathophysiology of ovarian cancer and implications for screening and prevention. American Journal of Obstetrics and Gynecology 213:262–267.
   PubMed Web of Science ®Google Scholar
• Panici PB, Maggioni A, Hacker N, Landoni F, Ackermann S, Campagnutta E, et al. 2005. Systematic aortic and pelvic lymphadenectomy versus resection of bulky nodes only in optimally debulked advanced ovarian cancer: a randomized clinical trial. Journal of the National Cancer Institute 97:560–566.
   PubMedGoogle Scholar
• Polcher M, Zivanovic O, Chi DS. 2014. Cytoreductive surgery for advanced ovarian cancer. Women's Health (London, England) 10:179–190.
   PubMedGoogle Scholar
• Rodriguez N, Miller A, Richard SD, Rungruang B, Hamilton CA, Bookman MA, et al. 2013. Upper abdominal procedures in advanced stage ovarian or primary peritoneal carcinoma patients with minimal or no gross residual disease: an analysis of Gynecologic Oncology Group (GOG) 182. Gynecologic Oncology 130:487–492.
   PubMed Web of Science ®Google Scholar